List view / Grid view
8 January 2016 | By Victoria White
The virtual laboratory will establish the environmental impact of drugs earlier in discovery and development while dramatically reducing both the cost of environmental assessments and the need for animal testing...
8 January 2016 | By Victoria White
The first-in-class candidate, CB1, has shown potent anti-metastatic activity, and with an impressive in vivo efficacy and safety profile...
8 January 2016 | By Victoria White
Researchers have shown that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells...
7 January 2016 | By Nicholas Jackson
Plans for the world’s first clinical trial for a vaccine targeting Alzheimer’s disease-like characteristics in those with Down's syndrome have been announced...
7 January 2016 | By Nicholas Jackson
Enterome announces collaboration with Johnson & Johnson Innovation focused on the discovery of novel targets and therapeutics for Crohn’s disease...
6 January 2016 | By Victoria White
Complix will use its proprietary Alphabody platform to deliver cell-penetrating alphabodies against up to two intracellular cancer targets of interest to MSD...
6 January 2016 | By Victoria White
Researchers tested the drug, commonly used to treat leukaemia, in zebrafish bred to carry Duchenne muscular dystrophy and recorded a 40% improvement in the condition of the fish...
6 January 2016 | By Victoria White
The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology have launched the project to develop a new immuno-oncology cellular therapy based on gene modifying T-cells to target solid tumours...
6 January 2016 | By Victoria White
As part of the collaboration, Enterome will use its metagenomic platform to support the discovery of potential novel agents derived from gut bacteria and directed to gastrointestinal targets...
5 January 2016 | By Victoria White
Oncodesign and Bristol-Myers Squibb have entered into a strategic collaboration to discover, develop and commercialise novel macrocyclic compounds...
5 January 2016 | By Victoria White
Renova and Research Development Foundation (RDF) have entered into a worldwide exclusive license agreement for RDF's portfolio of urocortin and stresscopin genes, as well as select peptides and proteins...
5 January 2016 | By Victoria White
NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumours, in combination with radiotherapy...
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
4 January 2016 | By Victoria White
The updated canSAR database will allow scientists working in the UK and across the globe to design new cancer treatments more effectively...
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
